Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2016 (2016), Article ID 6545861, 5 pages
http://dx.doi.org/10.1155/2016/6545861
Case Report

Acute Lymphoblastic Leukemia Arising in CALR Mutated Essential Thrombocythemia

1Cancer Molecular Diagnostics, St. James’s Hospital, Dublin 8, Ireland
2Department of Haematology, St. James’s Hospital, Dublin 8, Ireland
3Department of Clinical Genetics, Our Lady’s Children’s Hospital, Dublin 12, Ireland
4Department of Histopathology, St. James’s Hospital, Dublin 8, Ireland

Received 8 December 2015; Revised 6 January 2016; Accepted 10 January 2016

Academic Editor: Eduardo Arellano-Rodrigo

Copyright © 2016 Stephen E. Langabeer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Thiele, H. M. Kvasnicka, A. Orazi, A. Tefferi, and H. Gisslinger, “Essential thrombocythaemia,” in WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, pp. 48–50, International Agency for Research on Cancer, Lyon, France, 2008. View at Google Scholar
  2. S. E. Langabeer, H. Andrikovics, J. Asp et al., “Molecular diagnostics of myeloproliferative neoplasms,” European Journal of Haematology, vol. 95, no. 4, pp. 270–279, 2015. View at Publisher · View at Google Scholar
  3. T. Barbui, J. Thiele, A. M. Vannucchi, and A. Tefferi, “Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis,” Blood Cancer Journal, vol. 5, no. 8, article e337, 2015. View at Publisher · View at Google Scholar
  4. M. Czader and A. Orazi, “Acute myeloid leukemia and other types of disease progression in myeloproliferative neoplasms,” American Journal of Clinical Pathology, vol. 144, no. 2, pp. 188–206, 2015. View at Publisher · View at Google Scholar
  5. R. Hoffman, S. Estren, S. Kopel, S. M. Marks, and R. P. McCaffrey, “Lymphoblastic-like leukemic transformation of polycythemia vera,” Annals of Internal Medicine, vol. 89, no. 1, p. 71, 1978. View at Publisher · View at Google Scholar · View at Scopus
  6. T. A. Braich, T. M. Grogan, M. J. Hicks, and B. R. Greenberg, “Terminal lymphoblastic transformation in polycythemia vera,” The American Journal of Medicine, vol. 80, no. 2, pp. 304–306, 1986. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Aitchison, A. J. Black, and M. F. Greaves, “Polycythaemia rubra vera transforming to acute lymphoblastic leukaemia,” Clinical and Laboratory Haematology, vol. 9, no. 2, pp. 201–204, 1987. View at Publisher · View at Google Scholar · View at Scopus
  8. J. R. Neilson, W. N. Patton, M. D. Williams, E. E. Mayne, and B. J. Boughton, “Polycythaemia rubra vera transforming to acute lymphoblastic leukaemia with a common immunophenotype,” Journal of Clinical Pathology, vol. 47, no. 5, pp. 471–472, 1994. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Arai, M. Masuda, T. Okamura, M. Wada, T. Motoji, and H. Mizoguchi, “Polycythemia vera progressing to acute lymphoblastic leukemia after 13 years,” Rinshō Ketsueki, vol. 37, no. 12, pp. 1405–1409, 1996. View at Google Scholar · View at Scopus
  10. M. Camós, F. Cervantes, S. Montoto, J. C. Hernández-Boluda, N. Villamor, and E. Montserrat, “Acute lymphoid leukemia following polycythemia vera,” Leukemia & Lymphoma, vol. 32, no. 3-4, pp. 395–398, 1999. View at Google Scholar · View at Scopus
  11. A. M. O'Hea, W. Erber, N. T. J. O'Connor, and C. Bunch, “Acute transformation of essential thrombocythaemia: report of two cases,” Journal of Clinical Pathology, vol. 39, no. 12, pp. 1296–1298, 1986. View at Publisher · View at Google Scholar · View at Scopus
  12. P. T. Murphy, M. Sivakumaran, F. van Rhee, A. E. Watmore, and V. E. Mitchell, “Acute lymphoblastic transformation of essential thrombocythaemia,” British Journal of Haematology, vol. 89, no. 4, pp. 921–922, 1995. View at Google Scholar · View at Scopus
  13. K. K. Woronzoff-Dashkoff and C. E. Litz, “Acute lymphoblastic leukemia in a case of essential thrombocythemia,” American Journal of Clinical Pathology, vol. 106, no. 2, pp. 206–208, 1996. View at Google Scholar · View at Scopus
  14. L. C. Berkahn, J. Nelson, P. A. Ockelford, and P. J. Browett, “Transformation of essential thrombocythaemia to T cell acute lymphoblastic leukaemia,” Leukemia and Lymphoma, vol. 20, no. 3-4, pp. 347–349, 1995. View at Google Scholar · View at Scopus
  15. S. P. Shaheen II, S. S. Talwalkar, R. Simons, and L. Yam, “Acute lymphoblastic leukemic transformation in a patient with chronic idiopathic myelofibrosis and paroxysmal nocturnal hemoglobinuria,” Archives of Pathology & Laboratory Medicine, vol. 129, no. 1, pp. 96–99, 2005. View at Google Scholar · View at Scopus
  16. M. Sever, J. L. Jorgensen, I. Gurevich, M. Pinheiro, and S. Verstovsek, “Primary myelofibrosis with concurrent precursor T-cell lymphoblastic lymphoma of the spleen in a 26-year-old patient,” Leukemia Research, vol. 33, no. 11, pp. e186–e188, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. V. Jurisic, N. Colovic, T. Terzic, V. Djordjevic, and M. Colovic, “Transformation of primary myelofibrosis with 20q- in Philadelphia-positive acute lymphoblastic leukemia: case report and review of literature,” Pathology Research and Practice, vol. 208, no. 7, pp. 420–423, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Ohanian, V. Leventaki, S. Verstovsek et al., “Acute lymphoblastic leukemia arising in post-polycythemic myelofibrosis: a rare entity,” Leukemia and Lymphoma, vol. 53, no. 9, pp. 1839–1841, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. U. Bacher, T. Haferlach, W. Kern, H.-D. Harich, S. Schnittger, and C. Haferlach, “A case of chronic myeloproliferative syndrome followed by precursor T-cell acute lymphoblastic leukemia,” Cancer Genetics & Cytogenetics, vol. 175, no. 1, pp. 52–56, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. T. Klampfl, H. Gisslinger, A. S. Harutyunyan et al., “Somatic mutations of calreticulin in myeloproliferative neoplasms,” The New England Journal of Medicine, vol. 369, no. 25, pp. 2379–2390, 2013. View at Google Scholar
  21. E. Rumi, D. Pietra, V. Ferretti et al., “JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes,” Blood, vol. 123, no. 10, pp. 1544–1551, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. G. Rotunno, C. Mannarelli, P. Guglielmelli et al., “Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia,” Blood, vol. 123, no. 10, pp. 1552–1555, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Tefferi, E. A. Wassie, T. L. Lasho et al., “Calreticulin mutations and long-term survival in essential thrombocythemia,” Leukemia, vol. 28, no. 12, pp. 2300–2303, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Andrikovics, T. Krahling, K. Balassa et al., “Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations,” Haematologica, vol. 99, no. 7, pp. 1184–1190, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. A. P. Trifa, R. A. Popp, A. Cucuianu et al., “CALR versus JAK2 mutated essential thrombocythaemia—a report on 141 patients,” British Journal of Haematology, vol. 168, no. 1, pp. 151–153, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. A. M. Vannucchi, G. Masala, E. Antonioli et al., “Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms,” Cancer Epidemiology Biomarkers and Prevention, vol. 18, no. 7, pp. 2068–2073, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. P. Miltiades, E. Lamprianidou, I. K. Kerzeli et al., “Three-fold higher frequency of circulating chronic lymphocytic leukemia-like B-cell clones in patients with Ph-myeloproliferative neoplasms,” Leukemia Research, vol. 39, no. 11, pp. 1159–1165, 2015. View at Publisher · View at Google Scholar
  28. E. J. Baxter, L. M. Scott, P. J. Campbell et al., “Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders,” The Lancet, vol. 365, no. 9464, pp. 1054–1061, 2005. View at Google Scholar
  29. K. Haslam, S. E. Langabeer, K. Molloy, M. F. Mcmullin, and E. Conneally, “Assessment of CALR mutations in myelofibrosis patients, post-allogeneic stem cell transplantation,” British Journal of Haematology, vol. 166, no. 5, pp. 800–802, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Anastasi, M. J. Pettenati, M. M. Le Beau, H. C. Kwaan, and S. C. Weil, “Acute lymphoblastic leukemia in a patient with longstanding polycythemia vera: cytogenetic analysis reveals two distinct abnormal clones,” American Journal of Hematology, vol. 29, no. 1, pp. 33–37, 1988. View at Publisher · View at Google Scholar · View at Scopus
  31. L. Henry, S. Carillo, E. Jourdan, A. Arnaud, S. Brun, and T. Lavabre-Bertrand, “Association of essential thrombocythemia and chronic lymphocytic leukemia: absence of the V617F JAK2 mutation in the lymphoid compartment,” American Journal of Hematology, vol. 82, no. 6, pp. 500–501, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. C. Musolino, A. Allegra, G. Penna et al., “Absence of the V617F JAK2 mutation in the lymphoid compartment in a patient with essential thrombocythemia and B-chronic lymphocytic leukemia and in two relatives with lymphoproliferative disorders,” Acta Haematologica, vol. 122, no. 1, pp. 46–49, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Swierczek, J. Nausova, J. Jelinek et al., “Concomitant JAK2 V617F-positive polycythemia vera and B-cell chronic lymphocytic leukemia in three patients originating from two separate hematopoietic stem cells,” American Journal of Hematology, vol. 88, no. 2, pp. 157–158, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. M. E. Salama, S. I. Swierczek, T. Tashi, C. A. Warby, N. S. Reading, and J. T. Prchal, “Calreticulin mutated prefibrotic-stage myelofibrosis and PMF represent an independent clone from coexisting CLL,” Blood, vol. 124, no. 10, pp. 1691–1692, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. Nagai, M. Kawahara, N. Sugino et al., “A case of minor BCR-ABL1 positive acute lymphoblastic leukemia following essential thrombocythemia and originating from a clone distinct from that harboring the JAK2-V617F mutation,” Experimental Hematology & Oncology, vol. 3, no. 1, article 6, 2014. View at Publisher · View at Google Scholar
  36. J. Tao, X. Zhang, J. Lancet et al., “Concurrence of B-lymphoblastic leukemia and myeloproliferative neoplasm with copy neutral loss of heterozygosity at chromosome 1p harboring a MPL W515S mutation,” Cancer Genetics, vol. 207, no. 10–12, pp. 489–494, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Tefferi, E. A. Wassie, P. Guglielmelli et al., “Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients,” American Journal of Hematology, vol. 89, no. 8, pp. E121–E124, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. X. Cabagnols, J. P. Defour, V. Ugo et al., “Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution,” Leukemia, vol. 29, no. 1, pp. 249–252, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. D. Pietra, E. Rumi, W. Ferretti et al., “Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms,” Leukemia, 2015. View at Publisher · View at Google Scholar
  40. A. M. Vannucchi, E. Antonioli, P. Guglielmelli, A. Pardanani, and A. Tefferi, “Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal,” Leukemia, vol. 22, no. 7, pp. 1299–1307, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. T. Barbui, “The leukemia controversy in myeloproliferative disorders: is it a natural progression of the disease, a secondary sequel of therapy, or a combination of both?” Seminars in Hematology, vol. 41, no. 2, supplement 2, pp. 15–17, 2004. View at Google Scholar
  42. M. L. Randi, E. Ruzzon, G. Luzzatto, F. Tezza, A. Girolami, and F. Fabris, “Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders,” Haematologica, vol. 90, no. 2, pp. 261–262, 2005. View at Google Scholar · View at Scopus
  43. N. Gangat, A. P. Wolanskyj, R. F. McClure et al., “Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients,” Leukemia, vol. 21, no. 2, pp. 270–276, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. F. Palandri, L. Catani, N. Testoni et al., “Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy,” American Journal of Hematology, vol. 84, no. 4, pp. 215–220, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Björkholm, Å. R. Derolf, M. Hultcrantz et al., “Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms,” Journal of Clinical Oncology, vol. 29, no. 17, pp. 2410–2415, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. H. Pettersson, H. Knutsen, E. Holmberg, and B. Andréasson, “Increased incidence of another cancer in myeloproliferative neoplasms patients at the time of diagnosis,” European Journal of Haematology, vol. 94, no. 2, pp. 152–156, 2015. View at Publisher · View at Google Scholar · View at Scopus
  47. T. Krahling, K. Balassa, K. P. Kiss et al., “Co-occurrence of myeloproliferative neoplasms and solid tumors is attributed to a synergism between cytoreductive therapy and the common TERT polymorphism rs2736100,” Cancer Epidemiology Biomarkers & Prevention, vol. 25, no. 1, pp. 98–104, 2016. View at Publisher · View at Google Scholar
  48. S. Hermouet, E. Bigot-Corbel, and B. Gardie, “Pathogenesis of myeloproliferative neoplasms: role and mechanisms of chronic inflammation,” Mediators of Inflammation, vol. 2015, Article ID 145293, 16 pages, 2015. View at Publisher · View at Google Scholar